A Day Up For Ocugen, Inc.

Mon, Aug 10, 2020 at 05:34 PM

Ocugen, Inc. (OCGN:NASDAQ) jumped higher at $0.71, representing a gain of 28.2%. The stock got featured on our News Catalysts scanner on Mon 10 Aug 20 at 08:04 AM in the 'BIOTECH' category. From Fri 24 Jul 20, the stock recorded 40.00% Up Days and 54.55% Green Days

The stock spiked on Tue 28 Jul 20 at $0.96 with a volume of 301M+.

About Ocugen, Inc. (OCGN:NASDAQ)

Ocugen Inc is a clinical-stage biopharmaceutical company. It is focused on discovering, developing and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases. Ocugen offers a diversified ophthalmology portfolio that includes novel gene therapies, biologics, and small molecules and targets a broad range of high-need retinal and ocular surface diseases. Its product candidate includes OCU200 and OCU300 to treat diabetic macular edema (DME), diabetic retinopathy (DR) and wet age-related macular degeneration (AMD).

Top 10 Gainers:

Seres Therapeutics, Inc. (MCRB:NASDAQ), 389.22%
Omeros Corporation (OMER:NASDAQ), 50.88%
BiomX Inc. (PHGE:NYSEMKT), 42.1%
Commercial Vehicle Group, Inc. (CVGI:NASDAQ), 37.04%
Xtant Medical Holdings, Inc. (XTNT:NYSEMKT), 32.43%
Adamas Pharmaceuticals, Inc. (ADMS:NASDAQ), 31.75%
Trevena, Inc. (TRVN:NASDAQ), 31.51%
Sorrento Therapeutics, Inc. (SRNE:NASDAQ), 30.51%
LSB Industries, Inc. (LXU:NYSE), 29.75%
Ocugen, Inc. (OCGN:NASDAQ), 28.18%